In May 2025, Livzon Pharmaceutical Group Inc. (China), through Lian SGP Holding Pte. Ltd. (Singapore), signed an agreement to acquire approximately 64.81% of the shares of Imexpharm Pharmaceutical Joint Stock Company (stock code: IMP) for over 5.730 trillion VND (approximately 220.6 million USD). Current shareholders include SK Investment Vina III Pte. Ltd. (47.69%), Binh Minh Kim Investment JSC (9.75%), and KBA Investment JSC (7.37%).
By the end of 2025, the Ministry of Industry and Trade issued a decision stipulating four conditions for this acquisition. Lian SGP Holding Pte. Ltd. must not discriminate in trade conditions for similar transactions when supplying APIs in Vietnam, maintain a stable production strategy, and ensure the supply of quality antibiotics. In the year following the transaction’s completion, Livzon must report on positive impacts such as enhancing R&D capabilities and promoting technology transfer. Reporting must be conducted every three years and upon request by the National Competition Committee. This is one of the major deals, alongside SK’s divestments from Vingroup and Masan.
Leave a Reply